Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HuMAB companies -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (508)	4/3/2003 5:22:26 AM
From: nigel bates	Respond to of 1022

The market seemed to be listening to you yesterday. :-)

To: Icebrg who wrote (508)	4/16/2003 6:38:37 AM
From: Icebrg	Read Replies (2) \| Respond to of 1022

Medarex Announces Antibody Development Partnership With Pfizer Wednesday April 16, 6:00 am ET PRINCETON, N.J., April 16 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX - News) today announced a partnership with Pfizer, Inc. for the development of fully human therapeutic antibodies. Medarex plans to use its UltiMAb Human Antibody Development System(SM) to generate antibodies to disease targets. Pursuant to the agreement, Medarex could receive license fees and milestone payments as well as royalties on commercial sales of any products that may result from this agreement. "We are excited that Pfizer, a leading pharmaceutical company, now joins our growing list of top pharmaceutical companies that have access to our antibody technology," said Dr. Donald L. Drakeman, President and CEO of Medarex. Comment: For one reason or another they are always referring to these customer orders as partnerships. But apart from that. Positive for Medarex and their technology.